This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): PF-2341066, PF-2, 341, 066, PF-02341066, crizotinib, Zakori
Description: Crizotinib is an oral ATP-competitive small-molecule c-met/hepatocyte growth factor receptor (HGFR) aminopyridine tyrosine kinase and ALK-1 (anaplastic lymphoma kinase-1) inhibitor.
Abbott and Pfizer
In August 2009, Abbott announced entered into an agreement with Pfizer to develop a molecular diagnostic test intended to screen non-small cell lung cancer (NSCLC) tumors for the presence of gene rearrangements for PF-02341006.
OxOnc and Pfizer
In February 2013, Pfizer and OxOnc Development announced that the Companies entered into a co-development agreement to conduct a pivotal clinical trial of Xalkori for the treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring a ROS1 (c-ros) gene rearrangement (ROS1-positive). Under the terms of the agreement, OxOnc will provide funding and supervision for the trial, with the goal of generating the clinical data necessary for Pfizer to submit Xalkori for review by regulatory authorities for the treatment of advanced ROS1-positive NSCLC in the Asian region. If approved for this indication, OxOnc will be eligible to receive milestone payments from Pfizer. Additional terms...See full deal structure in Biomedtracker
Partners: OxOnc Development LP Merck KGaA
Additional information available to subscribers only: